Last reviewed · How we verify
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
This is a phase 2 study to investigate NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell lung cancer.
Details
| Lead sponsor | Yale University |
|---|---|
| Phase | PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 159 |
| Start date | Thu Feb 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Jun 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Advanced Non-small Cell Lung Cancer
Interventions
- NC318 800 mg
- NC318 400 mg
- Pembrolizumab
Countries
United States